{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:18:38Z","timestamp":1792819118004,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ejca.2011.01.018","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T14:17:56Z","timestamp":1298557076000},"page":"1578-1584","source":"Crossref","is-referenced-by-count":104,"title":["Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer"],"prefix":"10.1016","volume":"47","author":[{"suffix":"Jr.","given":"Laszlo","family":"Otvos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Kovalszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Riolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ferla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Olah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Sztodola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Nama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Molino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quirino","family":"Piubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Surmacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.01.018_b0005","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0010","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1078-0432.CCR-05-2281","article-title":"Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas","volume":"12","author":"Rodriguez-Pinilla","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/jwh.2008.1127","article-title":"The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review","volume":"18","author":"Vona-Davis","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ejca.2011.01.018_b0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/GCO.0b013e3282f40de9","article-title":"Triple negative breast cancer: current understanding of biology and treatment options","volume":"20","author":"Kang","year":"2008","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ejca.2011.01.018_b0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/annonc\/mdl306","article-title":"High-dose chemotherapy for triple negative breast cancer","volume":"18","author":"De Georgi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.01.018_b0030","first-page":"269","article-title":"Triple-negative breast cancer: novel therapies and new directions","volume":"63","author":"Pal","year":"2009","journal-title":"Mauritas"},{"key":"10.1016\/j.ejca.2011.01.018_b0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.01.018_b0040","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1055-9965.EPI-08-0544","article-title":"Triple-negative breast cancer and obesity in a rural Appalachian population","volume":"17","author":"Vona-Davis","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2011.01.018_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-009-0591-y","article-title":"The association of metabolic syndrome with triple-negative breast cancer","volume":"121","author":"Maiti","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2011.01.018_b0050","first-page":"2076","article-title":"Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women","volume":"17","author":"Phipps","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Rev"},{"key":"10.1016\/j.ejca.2011.01.018_b0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/bcr1638","article-title":"Obesity hormone leptin: a new target in breast cancer?","volume":"9","author":"Surmacz","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0060","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-05-1913","article-title":"Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli","volume":"12","author":"Garofalo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0065","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-08-0642","article-title":"Insulin-dependent leptin expression in breast cancer cells","volume":"68","author":"Bartella","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.onc.1210660","article-title":"Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1\u03b1","volume":"27","author":"Cascio","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2011.01.018_b0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0300985809357753","article-title":"Effect of obesity on breast cancer development","volume":"47","author":"Cleary","year":"2010","journal-title":"Vet Pathol"},{"key":"10.1016\/j.ejca.2011.01.018_b0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jcp.20472","article-title":"Leptin and cancer","volume":"207","author":"Garofalo","year":"2006","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejca.2011.01.018_b0085","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1471-2407-8-305","article-title":"Leptin\/HER2 crosstalk in breast cancer: in vitro study, preliminary in vivo analysis","volume":"8","author":"Fiorio","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2011.01.018_b0090","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-03-0749","article-title":"Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer","volume":"10","author":"Ishikawa","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/14728221003716466","article-title":"Leptin as a potential therapeutic target for breast cancer prevention and treatment","volume":"14","author":"Ray","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejca.2011.01.018_b0100","first-page":"3078","article-title":"Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features","volume":"122","author":"Xia","year":"2009","journal-title":"Chinese Med J"},{"key":"10.1016\/j.ejca.2011.01.018_b0105","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbamcr.2008.05.007","article-title":"Development of a pharmacologically improved peptide agonist of the leptin receptor","volume":"1783","author":"Otvos","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2011.01.018_b0110","doi-asserted-by":"crossref","unstructured":"Otvos L Jr., Kovalszky I, Scolaro L, et al. Peptide-based receptor antagonists for cancer treatment and appetite regulation. Biopolymers Pept. Sci 2011; in press, doi:10.1002\/bip.21377, PMID: 20564005.","DOI":"10.1002\/bip.21377"},{"key":"10.1016\/j.ejca.2011.01.018_b0115","doi-asserted-by":"crossref","first-page":"41038","DOI":"10.1074\/jbc.M404962200","article-title":"Mapping of the leptin binding sites and design of a leptin antagonist","volume":"279","author":"Van","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2011.01.018_b0120","first-page":"653","article-title":"Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30","volume":"20","author":"Lee-Huang","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2011.01.018_b0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1677\/erc.0.0100261","article-title":"How to target estrogen receptor-negative breast cancer?","volume":"10","author":"Rochefort","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2011.01.018_b0130","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1535-7163.MCT-05-0030","article-title":"The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer","volume":"4","author":"Sweeney","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2011.01.018_b0135","first-page":"1499","article-title":"Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status","volume":"30","author":"Ray","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2011.01.018_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5858\/2008-132-61-HTIAPS","article-title":"HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab","volume":"132","author":"O\u2019Malley","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2011.01.018_b0145","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1196\/annals.1397.013","article-title":"Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer","volume":"1095","author":"Koda","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2011.01.018_b0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1750-3639.2009.00323.x","article-title":"Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy","volume":"20","author":"Riolfi","year":"2010","journal-title":"Brain Pathol"},{"key":"10.1016\/j.ejca.2011.01.018_b0155","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1177\/009127000004001007","article-title":"Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb\/IIIa antagonist, using mixed-effects modeling (NONMEM)","volume":"40","author":"Zannikos","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2011.01.018_b0160","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1093\/jac\/dkq337","article-title":"Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections","volume":"65","author":"Ostorhazi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ejca.2011.01.018_b0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cyto.2008.03.009","article-title":"Human leptin induces angiogenesis in vivo","volume":"42","author":"Anagnostoulis","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.ejca.2011.01.018_b0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2009.12.002","article-title":"Tripe-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research","volume":"36","author":"Bosch","year":"2010","journal-title":"Cancer Treat Rev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:15:39Z","timestamp":1685963739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0959804911000633"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.01.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}